| INTRODUC TI ON
Acne vulgaris is estimated to affect 9.4% of the global population 1 and some degree of acne affects almost all people aged 15-17 years 2, 3 Acne has pleomorphic clinical presentations and can leave disfiguring scars that cause significant psychological distress.
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Current guidelines recommend the use of oral antibiotics plus topical retinoids and/or benzoyl peroxide for the treatment of moderately severe acne and assess response to antibiotics at 6-8 weeks to limit the formation of resistance in Propionibacterium acnes and other bacteria 2, [5] [6] [7] [8] They also recommend the use of maintenance therapy with a topical therapy such as retinoids when a patient has responded to treatment.
Photodynamic therapy (PDT) has shown potential for treatment of acne. 9 Mechanisms of action include transient antimicrobial,
anti-inflammatory, and sebaceous gland inhibition, and long-lasting sebaceous gland destruction. 10 When used with high-dose conditions (long incubation time and high fluence red light exposure),
PDT using topical 20% 5-aminolevulinic acid (ALA) and 16% methylaminolevulinate (MAL) have been shown to produce similar effects for acne treatment. 11 There is moderate-quality evidence of the usefulness of methyl aminolaevulinate photodynamic therapy with red light exposure. 12 Although progress has been made in the study of photodynamic therapy for acne, studies using standardized outcome measures and traditional acne treatments as active comparators are lacking. 2, 5, 12 The purpose of this study was to compare the efficacy and tolerability of ALA-PDT vs. adapalene gel plus oral doxycycline in patients with moderately severe facial acne vulgaris using a randomized, controlled, investigator-blinded and parallel-group study design. In this study the use of maintenance therapy with adapalene gel after both treatments was considered.
| PATIENTS AND ME THODS

| Study design
This prospective, randomized, controlled, comparative clinical trial enrolled patients with moderately severe inflammatory acne vulgaris defined by the Leeds revised acne grading system with modifications as numerous papules and pustules (40-100) usually with many comedones (40-100) and the occasional (up to 5) larger, deeper nodular inflamed lesions in the face. 13 Males and females aged 18-30 years and phototype according to Fitzpatrick from I to IV with facial acne vulgaris were enrolled in the study.
Exclusion criteria included photosensitivity disorder, autoimmune diseases, infectious diseases (HIV, herpes, TB), allergy or intolerance to tetracycline antibiotics, pregnant or lactating women and taking topical medication within 3 months and/or systemic treatment within the past 6 months. No other acne treatments were allowed during the study.
The protocol was approved by our institutional Ethics Committee 
| Treatment
The patients were randomized to receive ALA-PDT or doxycycline plus adapalene gel (1:1 ratio). A blocked random allocation sequence was created by computer generated random numbers, the random sequence was hidden by the use of codes.
Patients in the ALA-PDT group received two treatments, 2 weeks apart. The face was cleansed with a mild soap and 70% isopropyl alcohol. Then, in a darkroom, we applied 20% topical ALA in a hydroalcoholic vehicle (Levulan®, DUSA Pharmaceuticals Inc., Wilmington, MA, USA) onto the entire face avoiding the eye area and lips for 1.5 hours. ALA was completely removed after the incubation period, and the whole face was irradiated with a red light source (Waldman PDT 1200, Waldmann-Medizin-Technik, Villingen-Schwenningen, Germany) with a total radiation dose of 37 J/cm 2 for 9 minutes, 10~15 cm away from their face. In case of burning or pain during PDT, it was minimized by spritzing cool water and lowering the room temperature to 20°C. Intense visible light avoidance was recommended during 24-48 hours after drug application and they were educated to apply enough amounts of sunscreen hourly for 2 weeks.
The other group received doxycycline 100 mg/d orally plus adapalene gel 0.1% for 6 weeks. Patients were instructed to take a doxycycline 100 mg capsule at any time during the day between meals and to apply a light film of the adapalene gel to their face once daily at bedtime.
From the sixth week, both groups started adapalene gel 0.1% as maintenance therapy until 12 weeks of follow-up.
| Study assessment
All patients were evaluated at baseline, at weeks 6 and 12 after the start of treatment by two dermatologists who were unaware of the group assignment and avoided any oral interaction with patients or investigator that could expose the intervention. The two blinded dermatologist independently counted manually the number of inflammatory (papules, pustules, and nodules) and noninflammatory
facial lesions (open and closed comedones) and evaluated the supportive efficacy end points. The lesion counts were taken separately from the forehead, the left and right cheeks and the chin above the jaw line (excluding the nose, lips, and around the eyes). 14 During each visit, standardized front and bilateral 45° side photographs were taken with the same camera.
The primary efficacy end point was the reduction from baseline in total, inflammatory and noninflammatory lesion counts at week 6. Secondary end point was the reduction from baseline in total, inflammatory and noninflammatory lesion counts at week 12 using maintenance therapy.
Supportive efficacy end points were the improvement in the global assessment of acne severity, 15 patients`subjective assessment 11 and the reduction of facial area compromised by acne scarring and hyperpigmentation. All supportive efficacy end points were assessed at 12 weeks.
All the adverse effects were recorded detailedly at each PDT session, the day after the first PDT, before the second PDT session and at each follow-up visits (6 and 12 weeks for both treatment). The adverse effects were marked according to finding time, fading time, severity (grades: 0 = absent, 1 = mild, 2 = moderate, 3 = severe), treatment measure and outcome. 16 Pain during each session of PDT was assessed using a numerical Visual Analogue Scale (VAS) ranging from 0 to 10 (0 = no pain and 10 = worst imaginable pain).
| Statistical analysis
A sample size of 23 subjects per group was deemed necessary to detect a statistically significant difference in total lesion count between treatment groups based on the assumption that the correlation was the same in both groups and relatively low (0.01), the number of lesions per subject was equal in both groups with a mean of 100 and low variance and the percentage of improvement expected in the control group was 0.6 and in the PDT group was 0.7.
Statistical analysis was performed blindly and considered the intent-to-treat population. Comparison of the groups for nominal variables was performed using chi-square tests. To make comparisons of groups for quantitative variables, we used the McNemar test for related samples. Multivariate analysis was performed using Mann-Whitney tests. Statistical analysis was performed using SPSS version 17 and the value of P < 0.05 was considered statistically significant.
| RE SULTS
| Patients
Forty-six patients (20 female and 26 male) were enrolled in this study and randomized to 2 sessions of PDT-ALA 20% (n = 23, Group A) or to doxycycline 100 mg/d plus adapalene gel 0.1% topical (n = 23, Group B), then from the sixth week both groups started topical adapalene gel 0.1% as maintenance therapy (ClinicalTrials.gov number NCT01245946). The 46 enrolled patients received all study treatment and completed the study (Figure 1 ).
Demographic and baseline characteristics are listed in Table 1 .
The baseline-inflammatory lesions were different in both groups (P = 0.044), which was considered in the subsequent multivariate analysis, showing no effect on the results.
| Efficacy evaluation
Median reduction in numbers of total, noninflammatory and inflammatory acne lesions from baseline to weeks 6 and 12 are shown in Figure 2 . A trend toward greater efficacy of PDT compared to doxycycline plus adapalene in reducing inflammatory, noninflammatory, and total lesions at sixth week of follow-up was observed.
Significant difference was obtained in noninflammatory lesion count, which was lower in the Group A (P = 0.013) at week 6.
( Table 2 ).
At week 12 significant difference was obtained in the median percent reduction from baseline of total and inflammatory lesions considering the use of adapalene 0.1% gel in both groups.
Regarding multivariate analysis (Table 3) , the median percent reductions at weeks 6 and 12 of inflammatory, noninflammatory, and total lesions was found to be significantly higher in the group receiving PDT, except for inflammatory lesions at week 6 in which this relationship was not observed. Interestingly, the differences in this variable were related to the female sex, presenting a better response at week 6. At week 12, the difference in percent reduction was associated with patients with phototype III, which could be explained by the fact that around 50% of the patients included in this study corresponded to this phototype. Of the patients who had baseline acne scars, those in the PDT group (group A) reduced by a mean of 28% the numerical extent of acne scars compared with group B that showed a mean of 5% increase in the facial area compromised with acne scars.
However, mild pigmentation occurred in two patients (8.7%) with phototype III and IV in the group A at around 1 week after de PDT and disappeared within 3 months without medical intervention except for the use of adapalene. Three patients with initial facial hyperpigmentation due to acne lesions in group A persisted with the same affected areas but with decreased pigmentation at the end of the study. In group B, four patients presented initial facial hyperpigmentation that showed a 46% mean reduction of the pigmented area at 12 weeks.
Regarding patients`subjective assessment at week 12, 60% of patients in group A reported marked improvement compared with 46% of patients in group B (P = 0.460).
| Safety evaluation
In terms of pain of PDT, patients recorded a median score of 3 (range 1-7). The pain was generally well tolerated, no patient required to suspend or postpone the application of light and only about 60% of cases applying thermal water was needed during the session. No patients required oral analgesics. The second session was better tolerated, which we attribute to less anxiety about treatment application.
The main side effect detected was erythema, present in all cases.
It started immediately after the session and progressed in intensity during the first 24 hours and resolved around day 4 post-session F I G U R E 2 Mean percent reductions (p25-p75) in (A) inflammatory lesion counts compared with baseline, decreased by 61% (50%-72%) in group A vs. 58% (40%-73%) in group B (P = 0.423) at 6 wk and 84% (80%-88%) vs. 74% (58%-85%), respectively, at 12 wk (P = 0.020), (B) noninflammatory lesion counts, decreased by 55% (32%-60%) in group A vs. 41% (28%-52%) in group B at 6 wk (P = 0.055) and 72% (55%-82%) vs. 62% (48%-70%), respectively, at 12 wk (P = 0.057), and (C) total lesion counts, decreased by 53% (42%-60%) in group A vs. 44% (36%-54%) in group B at 6 wk (P = 0.097) and 79% (60%-85%) vs. 67% (52%-76%), respectively, at 12 wk (P = 0.026) (within a week). In 7 cases (35%) erythema was severe or very severe and 2 cases had to stop their daily activities for 2 days. As was decreasing erythema, desquamation began in 83% of cases to remit within the first 2 weeks. Thirty-nine percent of the patients had facial edema, which disappeared between 1 and 3 days. These side effects were of lesser intensity after the second session.
A common finding after the first session (78%) was a mild sterile 
| D ISCUSS I ON
This study indicates that ALA-PDT with red light offers promise as an alternative treatment for moderately severe inflammatory acne vulgaris that has a higher effectiveness than the combination of doxycycline and adapalene gel in reducing noninflammatory ant total lesions at 6 weeks of treatment and has a similar effect in the reduction of inflammatory lesions.
There were significantly superior reductions at 12 weeks in the combination of PDT group followed by adapalene gel relative to the doxycycline and adapalene gel group in total, inflammatory, and noninflammatory lesions.
The mechanism of action of PDT appears to involve selective damage to sebaceous glands, killing of Propionibacterium acnes, an effect on keratinocyte shedding and immunologic changes., 10, [17] [18] [19] Lesion counts, median (p25-p75) Group A (n = 23) Group B (n = 23) P-value 
TA B L E 3 Multivariate analysis using Mann-Whitney tests of the primary and secondary outcomes (Model of analysis of co variance or ANCOVA)
four elements that have a pivotal role in the formation of acne lesions.
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Deeper penetrating (red) light wavelengths are more likely to reach and activate porphyrins in sebaceous glands since they can reach dermis to more than 2 mm deep, 10 but red light is less effective in the eradication of P. acnes than blue light phototherapy without ALA; however, pretreatment with ALA improves the efficacy of red light causing strong bactericidal effect in vitro.
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High-dose PDT has been proven to cause a direct photodynamic destruction of sebaceous glands which apparently leads to a longlasting remission. 17 ALA-PDT can induce apoptosis of sebocytes and down-regulate their TLR-2 and TLR-4 expression, which could maintain the improvement of inflamed acne into late stages.
20
Results of our study regarding the effectiveness of oral doxycycline and adapalene gel group are similar to previous studies. PDT was significantly more effective than placebo PDT, as indicated by a greater median percent reduction in total inflammatory lesion counts at both week 6 (median reduction 63% vs. 28%) and week 12 (median reduction 54% vs. 20%). 24 These results are similar to our study at 6 weeks but at 12 weeks we obtained a greater median percent reduction in inflammatory lesion counts, which may be due to the use of adapalene gel as maintenance therapy after PDT.
The adverse event profile associated with ALA PDT was consistent with previous reports 25, 26 While pain was an issue in previous studies with 3 hours of incubation time 11, 16, 25, 27 the PDT regimen used in the current study with 1.5 hours of incubation showed more manageable pain and was better tolerated, these results were similar to previous studies with 1.5 hours of incubation. 9, 28 Because PDT is known to cause inflammation in the treated area, changes in pigmentation are an expected outcome, especially in darker skin types. Some authors have advised reducing the total light dose, strength of the photosensitizer, and incubation time in these patients to avoid dyschromia. 29 In our study, baseline postinflammatory hyperpigmentation improved at 12 weeks with a greater difference in the group of doxycycline plus adapalene for 12 weeks vs PDT plus adapalene for 6 weeks. The efficacy of topical adapalene 0.1% as monotherapy for hyperpigmentation has been reported.
30
The use of adapalene after PDT would have the advantage of maintaining and enhancing the effect of PDT as well as reducing possible post-inflammatory hyperpigmentations.
Our results are limited by the relatively small sample size, which was calculated considering the minimum to achieve statistical significance due to the budgetary limitations of this independent study. The lack of statistical significance in some variables could be attributed to the sample size, that is, with a larger sample size it is possible that values of uncertain significance or those close to 0.05 would have been clarified.
The other limitation of the study is the short follow-up time due to the risk of acne recurrence after PDT. We use adapalene gel after PDT as maintenance tre a tment following the current guidelines that recommend the use of retinoids after a successful treatment of acne. [5] [6] [7] [8] With t h is we wanted to evaluate the potential of this treatment in the real world, as an alternative to current treatments and we observed greater effectiveness in this treatment modality at 12 weeks. One year after the end of the study all patients were contacted via email. Fifteen patients from the PDT group and 9 patients from the doxycycline g r oup answered a questionnaire. Patients in the PDT group continued with topical adapalene for an average of 3.7 months after the end of the study and only two patients (13%) had a mild reactivation near to the year. Patients in the doxycycline group continued with topical adapalene for an average of 1.5 months and 6 patients (67%) had a mild or moderate reactivation between 6 to 12 months later.
PDT is very promising and there are practical advantages associated with this acne treatment modality. Some patients may benefit aesthetically from ALA PDT for acne, which has been associated with reduction of skin oiliness, "pore" (sebaceous follicle) size, and skin texture improvement. 25, 31 PDT has apparently similar efficacy to oral isotretinoin regarding the ability of inhibit sebaceous gland function and to produce prolonged remission of acne vulgaris. 17, 25, 32 Previous studies indicated that topical ALA is a nontoxic, naturally occurring substance that targets cells by porphyrin synthesis; it does not lead to antibiotic resistance or have a potential teratogenic risk.
33
PDT would also have the advantages of happy patients' opinions due to rapid response as reported by our patients and greater compliance to the treatment and subsequent use of adapalene, since we observed a lower adherence to adapalene in the doxycycline group.
Although all patients presented with erythema instantly after PDT therapy, most patients with moderately severe inflammatory acne showed good tolerance and effectiveness to ALA-PDT therapy with 1.5 hours of incubation. This treatment shows great promise, but additional studies are needed to optimize the treatment procedure to ensure a long-lasting effect, while at the same time minimizing the potential for side-effects.
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